Gender difference in response predictors after 1-year exenatide therapy twice daily in type 2 diabetic patients: A real world experience

Diabetes, Metabolic Syndrome and Obesity

Volumn 6, Issue , 2013, Pages 123-129

  Anichini, Roberto ^a   Cosimi, Sabrina ^b   Di Carlo, Alberto ^c   Orsini, Paola ^d   De Bellis, Alessandra ^a   Seghieri, Giuseppe ^a   Franconi, Flavia ^e   Baccetti, Fabio ^f  

^a Spedali Riuniti   (Italy)

^b Versilia Hospital   (Italy)

^c Hospital of Lucca   (Italy)

^d Livorno Hospital   (Italy)

^e UNIVERSITY OF SASSARI   (Italy)

^f Asl 1 Toscana   (Italy)

Author keywords

Exenatide BID; GLP 1 agonist therapy; Real world setting; Type 2 diabetes

Indexed keywords

EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; SULFONYLUREA;

ADULT; ARTICLE; BODY MASS; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC INDEX; HOMEOSTASIS MODEL ASSESSMENT B; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PREDICTION; SEX DIFFERENCE; TREATMENT DURATION; VOMITING; WEIGHT REDUCTION;

EID: 84876054019     PISSN: 11787007     EISSN: None     Source Type: Journal    
DOI: 10.2147/DMSO.S42729     Document Type: Article

References (31)

1. Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med. 1996;124(1 Pt 2):136-145.
2. Stettler C, Allemann S, Jüni P, et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. Am Heart J. 2006;152(1):27-38.
3. Alvarez Guisasola F, Tofé Povedano S, Krishnarajah G, Lyu R, Mavros P, Yin D. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. Diabetes Obes Metab. 2008;10 Suppl 1:25-32.
4. Weber KK, Lohmann T, Busch K, Donati-Hirsch I, Riel R. High frequency of unrecognized hypoglycaemias in patients with type 2 diabetes is discovered by continuous glucose monitoring. Exp Clin Endocrinol Diabetes. 2007;115(8):491-494.
5. Inzucchi SE, Bergenstal RM, Buse JB, et al; for American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-1379.
6. Ahrén B. GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors. Curr Diab Rep. 2007;7(5):340-347.
7. Mikhail N. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes. Expert Opin Investig Drugs. 2008;17(6):845-853.
8. Scott LJ. Exenatide extended-release: a review of its use in type 2 diabetes mellitus. Drugs. 2012;72(12):1679-1707.
9. Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology. 2003;144(12):5149-5158.
10. Li YZ, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem. 2003;278(1):471-478.
11. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998; 101(3):515-520.
12. Baggio LL, Huang Q, Brown TJ, Drucker DJ. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes. 2004;53(9):2492-2500.
13. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36(8):741-744.
14. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298(2):194-206.
15. Barnett AH. New treatments in type 2 diabetes: a focus on the incretin-based therapies. Clin Endocrinol (Oxf). 2009;70(3):343-353.
16. Monami M, Marchionni N, Mannucci E. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. Eur J Endocrinol. 2009;160(6):909-917.
17. Norris SL, Lee N, Thakurta S, Chan BK. Exenatide efficacy and safety: a systematic review. Diabet Med. 2009;26(9):837-846.
18. Shyangdan DS, Royle PL, Clar C, Sharma P, Waugh NR. Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis. BMC Endocr Disord. 2010;10:20.
19. NHS National Institute for Health and Clinical Excellence. Clinical guidelines CG87: Type 2 diabetes - newer agents (partial CG66) (CG87) [homepage on the Internet]. London, UK: NHS National Institute for Health and Clinical Excellence; 2009. Available from: http://www.nice. org.uk/cg87. Accessed March 25, 2013.
20. Buysschaert M, Preumont V, Oriot PR, et al. One-year metabolic out-comes in patients with type 2 diabetes treated with exenatide in routine practice. Diabetes Metab. 2010;36(5):381-388.
21. Bergenstal RM, Garrison LP Jr, Miller LA, et al. Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting. Curr Med Res Opin. 2011;27(12):2335-2342.
22. Adam TC, Westerterp-Plantenga MS. Nutrient-stimulated GLP-1 release in normal-weight men and women. Horm Metab Res. 2005; 37(2):111-117.
23. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487-1495.
24. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-853.
25. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):854-865.
26. Marchetti P, Dotta F, Lauro D, Purrello F. An overview of pancreatic beta-cell defects in human type 2 diabetes: implications for treatment. Regul Pept. 2008;146(1-3):4-11.
27. Charpentier G, Vaur L, Halimi S, et al; for DIAMETRE. Predictors of response to glimepiride in patients with type 2 diabetes mellitus. Diabetes Metab. 2001;27(5 Pt 1):563-571.
28. Pencek R, Blickensderfer A, Li Y, Brunell SC, Anderson PW. Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index. Postgrad Med. 2012;124(4):21-32.
29. Colditz GA, Willett WC, Stampfer MJ, et al. Weight as a risk factor for clinical diabetes in women. Am J Epidemiol. 1990;132(3):501-513.
30. Seghieri G, Tesi F, Anichini R, et al. Gender modulates the relationship between body weight and plasma glucose in overweight or obese subjects. Diabetes Res Clin Pract. 2008;80(1):134-138.
31. Wannamethee SG, Papacosta O, Lawlor DA, et al. Do women exhibit greater differences in established and novel risk factors between diabetes and non-diabetes than men? The British Regional Heart Study and British Women's Heart Health Study. Diabetologia. 2012;55(1):80-87.